Modis is a biopharmaceutical company focused on developing therapies for mitochondrial DNA depletion disorders. The company’s lead program is currently in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease that has no current treatment options and is often fatal. Acquired by: Zogenix